Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2248384 | 0.82 | GRIN2B (0.42) | ALDH1A1L3MBTL1CHRM4NPC1RAB9A | |
| SCHEMBL2248064 | 0.79 | TMEM97 (0.38) | CHRM4CHRM2CHRM1CHRM3 | |
| SCHEMBL12367369 | 0.79 | TMEM97 (0.38) | CHRM4CHRM2CHRM1CHRM3 | |
| SCHEMBL3398221 | 0.78 | GPR119 (0.35) | CCR5CHRM4CHRM2CHRM1CHRM3 | |
| SCHEMBL12356460 | 0.77 | GPR119 (0.42) | ENPP2MAPT | |
| SCHEMBL2245448 | 0.76 | GPR119 (0.40) | MAPTNPC1RAB9ALMNATP53 | |
| SCHEMBL2245181 | 0.76 | GPR119 (0.40) | MAPTNPC1RAB9ALMNATP53 | |
| SCHEMBL2243540 | 0.74 | MAPT (0.40) | ENPP2MAPTHSP90AB1 | |
| SCHEMBL2246278 | 0.73 | MAPT (0.31) | MAPTHSP90AB1 | |
| SCHEMBL3403746 | 0.73 | MAPT (0.35) | MAPTLMNAHSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | claimed |
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190263-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | ALDH1A1 1462/4885L3MBTL1 4812/4885CCR5 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.